CMS Moratorium Could Spur Hospice, Home Health M&A

Why It Matters

The moratorium redirects growth capital toward consolidation, accelerating M&A and potentially inflating transaction prices while increasing regulatory risk for acquirers. This shift reshapes competitive dynamics in the hospice and home‑health markets.

Key Takeaways

• CMS halts new hospice enrollment for six months
• M&A activity expected to rise as de‑novo growth stalls
• Add‑on deals likely to command premium valuations
• Buyers must intensify compliance due‑diligence

Pulse Analysis

The CMS enrollment moratorium, announced in May, represents a decisive regulatory response to a surge in fraudulent hospice providers. By pausing new Medicare entrants for six months, the agency aims to tighten oversight and protect federal health‑care dollars. While the freeze curtails organic expansion, it also creates a vacuum that investors are eager to fill through strategic acquisitions, especially as the sector rebounds from a multi‑year slump in dealmaking.

Private‑equity firms and publicly traded health‑care companies are now pivoting toward add‑on acquisitions to expand their platforms. Analysts note that the current environment, with limited de‑novo opportunities, drives buyers to compete for existing assets, pushing hospice valuations higher. Mertz Taggart’s managing partner predicts a "small net positive" in M&A volume, with premium pricing especially for add‑on targets that complement established platforms. This competitive pressure could accelerate consolidation, creating larger, more integrated service providers capable of achieving economies of scale.

The heightened M&A activity brings its own challenges. Legal experts warn that intensified due‑diligence will be essential to avoid inheriting compliance issues that could attract CMS scrutiny. Transaction structures may evolve to mitigate regulatory risk, and buyers will need robust post‑deal integration plans. Should the moratorium be extended beyond the initial six months, the incentive for consolidation could intensify further, reshaping the hospice and home‑health landscape for years to come.